Pharmacoeconomic review report: Dexamethasone (Ozurdex) (Allergan Inc.)
Dexamethasone intravitreal implant (Ozurdex) is a glucocorticoid receptor agonist that targets angiogenic vascular-endothelial growth factor (VEGF) and pro-inflammatory pathways of diabetic macular edema (DME). It received a Health Canada notice of compliance on April 16, 2015 for the treatment of D...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, November 2018
|
| Edition: | Final with redactions |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references